Australia markets open in 7 hours 32 minutes

Allogene Therapeutics, Inc. (ALLO)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
18.47+0.26 (+1.40%)
As of 10:26AM EST. Market open.
Full screen
Loading interactive chart…
  • GlobeNewswire

    Allogene Therapeutics Announces Conference Call to Review ALPHA, ALPHA2 and UNIVERSAL Phase 1 Data Presented at the 2021 American Society of Hematology Annual Meeting

    Conference Call and Webcast Scheduled for Monday, December 13, 2021 at 1:30 PM PT/4:30 PM ET SOUTH SAN FRANCISCO, Calif., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management will host a conference call to review data to be presented at the American Society of Hematology Annual Meeting from the ALPHA and ALPHA2 Phase 1 t

  • GlobeNewswire

    Allogene Therapeutics Announces Participation in Five Upcoming Virtual Investor Conferences

    SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to participate in five upcoming virtual investor conferences. Cowen's 5th Annual IO Next SummitMonday, November 15, 20218:45 AM PT/11:45 AM ET Stifel 2021 Virtual Healthcare ConferenceTuesday, November 16, 202111:00 AM PT/2:00 PM ET J

  • Motley Fool

    Cathie Wood's Buying Beam Therapeutics -- Should You?

    Over the past year, shares of Beam Therapeutics (NASDAQ: BEAM) have soared over 174% higher. This is the firm founded and still run by Cathie Wood, one of the world's most famous investors. Beam Therapeutics is pioneering the use of a new base editing technique in the development of new gene therapies.